版本:
中国

BRIEF-Kempharm receives clearance from FDA to initiate clinical program for KP201/IR

Nov 29 Kempharm Inc :

* Kempharm receives clearance from FDA to initiate clinical program for KP201/IR, a single-entity benzhydrocodone HCL immediate release abuse-deterrent prodrug for the treatment of acute pain

* Kempharm expects to conduct human clinical trials of KP201/IR in 2017

* Intend to initiate human clinical trials of KP201/IR in first half of 2017

* Remain on target for a potential submission in 2018 of KP201/IR new drug application Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐